

Date: 06/04/2022

FREEDOM OF INFORMATION REQUEST FOI/016117 – Dermatology (biologics)

I am analysing the usage of new biologic medications for the treatment of dermatological conditions. I would greatly appreciate if you could answer the following question.

How many patients were treated in February 2022 (or latest available month) by the dermatology department with the following drugs:

Abrocitinib(Cibinqo) - 0
Baricitinib(Olumiant) - 0
Bimekizumab(Bimzelx) - 0
Brodalumab(Kyntheum) - 2
Dupilumab(Dupixent) - 15
Ixekizumab(Taltz) - 0
Risankizumab(Skyrizi) - 3
Guselkumab(Tremfya) - 12
Secukinumab(Cosentyx) - 20
Tildrakizumab(Ilumetri) - 2
Tralokinumab(Adtralza) - 0
Upadacitinib(Rinvoq) - 0
Ustekinumab(Stelara) - 8